Solute carrier transporter superfamily member SLC16A1 is a potential prognostic biomarker and associated with immune infiltration in skin cutaneous melanoma. Issue 1 (1st January 2021)

• Record Type: Journal Article
• Authors: Xie, Jiaheng; Zhu, Zhechen; Cao, Yuan; Ruan, Shujie; Wang, Ming; Shi, Jingping
• Is Part Of: Channels. Volume 15:Issue 1(2021)
• Page Start: 483
• Page End: 495
• Publication Date: 2021-01-01
• Subjects: melanoma -- bioinformatics -- immunotherapy -- solute carrier -- transporter; Ion channels -- Periodicals; 572.3
• DOI: 10.1080/19336950.2021.1953322
• Languages: English
• ISSNs: 1933-6950

Abstract

ABSTRACT: Melanoma is a type of cancer with a relatively poor prognosis. The development of immunotherapy for the treatment of patients with melanoma has drawn considerable attention in recent years. It is of great clinical significance to identify novel promising prognostic biomarkers and to explore their roles in the immune microenvironment. The solute carrier (SLC) superfamily is a group of transporters predominantly expressed on the cell membrane and are involved in substance transport. SLC16A1 is a member of the SLC family, participating in the transport of lactate, pyruvate, amino acids, ketone bodies, etc. The role of SLC16A1 in tumor immunity has been recently elucidated, while its role in melanoma remains unclear. In this study, bioinformatics analysis was performed to explore the role of SLC16A1 in melanoma. The results showed that high SLC16A1 expression was correlated with decreased overall survival in patients with melanoma. The genes co-expressed with SLC16A1 were significantly enriched in metabolic regulation, protein ubiquitination, and substance localization. Moreover, SLC16A1 was correlated with the infiltration of immune cells. In conclusion, SLC16A1 is a robust prognostic biomarker for melanoma and may be used as a novel target in immunotherapy.